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Background: To investigate the efficacy and safety of FOLFIRI plus bevacizumab regimen with irinotecan (180 mg/m2)
in patients with advanced or recurrent colorectal cancer who were of the wild-type or heterozygous group for
UGT1A1*28 and *6 polymorphisms and discontinued to oxaliplatin-based regimen, prospectively.
Methods: The study population consisted of patients who had discontinued oxaliplatin-based regimen for any reason.
The primary endpoint was the response rate. FOLFIRI and bevacizumab regimen [irinotecan: 180 mg/m2, 5-fluorouracil
infusion: 2400 mg/m2, 5-fluorouracil bolus: 400 mg/m2, levofolinate calcium: 200 mg/m2, bevacizumab: 5 mg/kg] was
repeated every 2 weeks for up to 24 cycles.
Results: Ninety-four patients were enrolled; 93 patients were evaluated on safety, 94 patients on efficacy. The response
rate was 10.1% (95% confidence interval (CI): 4.7-18.3%). The median time to treatment failure, progression-free survival,
and overall survival were 4.1 months (95% CI: 2.8-4.8 months), 5.4 months (95% CI: 4.1-6.2 months), and 14.5 months
(95% CI: 11.8-17.0 months), respectively. The treatment-related death was 1.1%, and the early death ≤30 days after the
last study treatment was 1.1%. The incidence of grade 3 or higher adverse events was 60.2% for neutropenia, 23.7% for
leukopenia, 9.7% for diarrhea, 6.5% for anorexia, and 5.4% for fatigue. All these adverse events and other adverse events
were controllable.
Conclusions: FOLFIRI plus bevacizumab regimen with an initial irinotecan dose of 180 mg/m2 exhibited an adequate
antitumor effect and was confirmed to be manageable and tolerable in Japanese patients with advanced or recurrent
colorectal cancer, who had discontinued oxaliplatin-based regimen.
Trial registration: UMIN000001817.Background
In 2008, the number of newly diagnosed patients with
colorectal cancer exceeded 1,200,000 worldwide, result-
ing in estimated 608,700 deaths. Colorectal cancer is the
third most common cancer among males and the second
among females [1]. In Japan, 357,305 people died of can-
cer in 2011; of them, colorectal cancer accounted for
11.7% among males as the third most common cancer* Correspondence: m.suenaga@jfcr.or.jp
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unless otherwise stated.behind lung cancer and gastric cancer, and 14.5% among
females as the most common cause of cancer death [2].
Chemotherapy for advanced or recurrent colorectal can-
cer in Europe and the United States used to be centered
on 5-fluorouracil (5-FU) given either as a single agent or
in combination with other agents [3]. After the approval
of irinotecan and oxaliplatin, however, several clinical
trials were reported demonstrating the utility of first-line
treatment with FOLFIRI [irinotecan + 5-FU bolus + 5-FU
infusion + LV] regimen and FOLFOX [oxaliplatin + 5-FU
bolus + 5-FU infusion + LV] regimen [4-6].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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progression-free survival (PFS) by the introduction of
molecular-targeted agents has been reported [7-9].
Moreover, various studies indicated the possibility that
continuation of bevacizumab after first progression (bev-
acizumab beyond progression; BBP) might contribute to
prolonged survival, leading to studies on combined use
of molecular-targeted agents [10-12].
However, there have been few reports on FOLFIRI
regimen or FOLFIRI plus bevacizumab regimen used in
previously-treated patients. Besides, no prospective study
using an irinotecan dose of 180 mg/m2, the same dose
used in FOLFIRI regimen or FOLFIRI plus bevacizumab
regimen used in Europe and the United States [5,6], has
been reported in Japan.
On the other hand, many genetic researches on UDP
glucuronyl transferase (UGT) which is the major meta-
bolic enzyme of an active metabolite of irinotecan, a key
drug for chemotherapy of colorectal cancer, have been
reported in recent years. Irinotecan was associated with
serious adverse events (especially neutropenia) particu-
larly in patients with a variant UGT1A1*28, a poly-
morphism of UGT [13,14]. Satoh et al. reported that
irinotecan could be used more safely in patients of the
wild-type or heterozygous group for UGT1A1*28 and *6
polymorphisms because the AUC0-24h of SN-38 was
lower and thus the incidences of grade 3 or higher neu-
tropenia and leukopenia were lower in those patients
compared with the homozygous group [15].
Consequently, we conducted the first prospective mul-
ticenter phase II study in Japan to investigate the efficacy
and safety of FOLFIRI plus bevacizumab regimen with
the irinotecan dose set to 180 mg/m2 in compliance with
Good Clinical Practice (GCP) guidelines in patients with
advanced or recurrent colorectal cancer who were of the
wild-type or heterozygous group for UGT1A1*28 and *6
polymorphisms and had discontinued oxaliplatin-based
regimen.
Methods
Patients who met the following major eligibility criteria
were enrolled: aged ≥20 years; Eastern Cooperative Oncol-
ogy Group performance status (ECOG PS) of ≤ 1; histo-
logically confirmed colorectal cancer; discontinuation for
refractory or intolerable to first-line oxaliplatin-based
regimen; not previously treated with irinotecan; both
UGT1A1*28 and *6 polymorphisms were wild-type (wild-
type group) or one of them was heterozygous (heterozy-
gous group); at least one measurable lesion; life expectancy
≥3 months; adequate function of principal organs; and
written informed consent. This study was conducted ac-
cording to a protocol that complied with the Declaration
of Helsinki and GCP, and was approved by the Ins-
titutional Review Board of each institution as follows:institutional review board of Cancer Institute Hospital of
the Japanese Foundation for Cancer Research, institutional
review board of National Hospital Organization Shikoku
Cancer Center, institutional review board of Aichi Cancer
Center Hospital, institutional review board of Chiba
Cancer Center, institutional review board of Japanese Red
Cross Kitami Hospital, institutional review board of
National Kyushu Cancer Center, institutional review board
of Hyogo Cancer Center, and institutional review board
of Southern Tohoku General Hospital. The study was




In this study, FOLFIRI plus bevacizumab regimen
[irinotecan (Yakult Honsha Co., Ltd, Tokyo, Japan):
180 mg/m2, 5-FU bolus: 400 mg/m2, 5-FU infusion:
2400 mg/m2, levofolinate calcium: 200 mg/m2, bevacizu-
mab: 5 mg/kg] were administered biweekly. The study
treatment was defined as FOLFIRI plus bevacizumab
and sLV5FU2 with/without bevacizumab after discon-
tinuation of irinotecan, and the treatment was to be con-
tinued for up to 24 cycles unless it was discontinued at
the discretion of the physician due to progression of the
primary disease, onset of adverse events, patient refusal,
tumor resection, etc. Even in the patients who had the
doses of 5-FU reduced during the first-line treatment,
the study treatment was started at the doses of 5-FU de-
scribed above. In addition, the study treatment was de-
layed unless all of the following criteria were met on the
day of administration or the previous day: leukocyte
count ≥ 3,000/mm3; platelet count ≥ 100,000/mm3; aspar-
tate aminotransferase ≤ 100 IU/L; alanine aminotrans-
ferase ≤ 100 IU/L; total bilirubin ≤ 1.5 mg/dL; serum
creatinine ≤ 1.50 mg/dL; protein urine, bleeding, stoma-
titis and fatigue grade 1≥; and no diarrhea.
The irinotecan dose was reduced to 150 mg/m2,
125 mg/m2 or 100 mg/m2 if grade 4 neutropenia or
grade 3 or higher thrombocytopenia or diarrhea oc-
curred. As for the doses of 5-FU, the infusion dose was
reduced to 2,000 mg/m2 or 1,600 mg/m2 and the bolus
dose to 200 mg/m2 when grade 4 neutropenia or grade 3
or higher thrombocytopenia, diarrhea, stomatitis or
hand-foot syndrome occurred. No post chemotherapy
was specified in this study.
The dose intensity (DI) was calculated as the ratio of
the total dose (expressed in milligrams) per square meter
divided by total treatment duration. The relative DI
(RDI) was calculated as the ratio of the DI actually deliv-
ered to that of the DI proposed in the protocol.
The primary endpoint was response rate, and the sec-
ondary endpoints were time to treatment failure (TTF),
PFS, OS, dose intensity, and incidence of adverse events.
Tumor response was evaluated according to the RECIST



















Poorly-differentiated adenocarcinoma 9 10.1
Mucinous adenocarcinoma 3 3.4




Wild-type group 52 58.4
Heterozygous group 37 41.6
First-line treatment
Refractory (PD) / intolerable (adverse event) to
oxaliplatin-based treatment
46/43 51.7/48.3
With/without bevacizumab 69/20 77.5/22.5
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verse events were evaluated according to the NCI-CTC
(ver. 3.0).
Duration of stable disease, TTF, PFS and OS were cal-
culated using the Kaplan-Meier method. Duration of
stable disease was defined as the period from the date of
the first dose to the date of the first imaging showing
progressive disease by the non-institutional review. TTF
was defined as the time from the date of the first dose to
the date of treatment discontinuation, or the date of pro-
gression, or the date of death from any cause, whichever
was earlier. Data on patients who had completed 24 cy-
cles of treatment or who discontinued treatment for
tumor resection were censored at the date of final obser-
vation. PFS was defined as the time from the date of the
first dose to the date of progression or the date of death
from any cause, whichever was earlier. Patients undergo-
ing resection of metastases were censored at the time of
surgery. OS was defined as the time from the date of the
first dose of the study treatment to the date of death
from any cause.
In the V308 study, the response rate of FOLFIRI regi-
men (CPT-11 180 mg/m2) in FOLFOX-received patients
who discontinued the treatment due to progression of
the primary disease or adverse event was reported to be
4%. Also, the E3200 study reported that the response
rate was 8.6% in the FOLFOX group and 22.7% in the
FOLFOX plus bevacizumab group. Based on these re-
sults, the expected response rate of FOLFIRI plus beva-
cizumab regimen was set to be 12% in this study [6,16].
At this rate, 84 patients would be required to make the
width of 95% confidence interval (CI) of the response
rate about 15%, and therefore 90 patients were set to
take into account those who would be excluded from
the analysis set.
The chi-square test for independence (Fisher’s exact
test when the expected value was <5) was performed to
compare the response rate in patients who received first-
line chemotherapy with/without bevacizumab. To com-
pare PFS and OS of the first-line treatment with/without
bevacizumab, point estimates of the hazard ratio (HR)
were made by Cox regression analysis (proportional haz-
ards model) and the log-rank test was performed. The
chi-square test for independence (Fisher’s exact test
when the expected value was <5) was employed to com-




Between May 2009 and November 2010, 94 patients
from 18 institutions were registered. Of these, 1 patient
was withdrawn before starting the study treatment, 1 pa-
tient was found to be not eligible after enrollment, 1patient became a candidate for surgery after 1 cycle of
treatment, and 2 patients were found to have no target
lesion by the independent extramural review board be-
fore enrollment in this study. Consequently, 93 patients,
excluding the patient who did not receive the study
treatment, were included in the safety analysis set, and
89 patients were included in the efficacy analysis set. De-
tails of patient characteristics are shown in Table 1.
There was no patient who treated with anti-EGFR agents
as a first-line chemotherapy.
Treatment
The median cycles of the study treatment was 8.0 (range:
1–24), and 7 patients (7.9%) were able to continue FOL-
FIRI plus bevacizumab throughout the 24 cycles. The
median RDI of each agent was 80.0% for irinotecan,
75.7% for 5-FU bolus, 80.0% for 5-FU infusion, and
80.0% for bevacizumab. Dose modification of each agent
Table 2 Dose modification of Irinotecan and 5-fluorouracil (5-FU) (N = 89)
Dose Level Dose (mg/m2) N % Duration until modification (days)
Median Range
Irinotecan 0 180 52 58.4 - -
−1 150 37 41.6 33.0 (14–448)
−2 125 12 13.5 76.5 (14–146)
−3 100 3 3.4 112.0 (47–181)
5-FU (bolus/infusion)* 0 400/2,400 55 61.8 - -
−1 400/2,000 34 38.2 47.5 (14–448)
−2 0/1,600 9 10.1 82.0 (33–301)
*No patient had the dose of only bolus or infusion of 5-FU reduced.
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the irinotecan dose were neutropenia in 10 patients
(11.2%) and diarrhea in 6 patients (6.7%), and those for
5-FU were neutropenia in 12 patients (13.5%), diarrhea
in 2 patients (2.2%), and stomatitis in 2 patients (2.2%).
There were 26 patients (29.2%) who had the dose of
first-line 5-FU reduced. Of these, 17 patients (19.1%)
also had the 5-FU dose reduced in this study, and 9 pa-
tients (10.1%) didn’t. Four patients (4.5%) had the doses
of both irinotecan and 5-FU reduced simultaneously due
to diarrhea.
The reasons for discontinuing the study treatment in-
cluded progression of the primary disease in 48 patients
(51.6%), adverse events in 24 patients (25.8%), patient re-
fusal in 6 patients (6.5%), and discretion of the physician
in 9 patients (9.7%).
Efficacy
The results of the efficacy analysis are shown in Table 3.
The response rate was 10.1% (95% CI: 4.7-18.3%), and the
disease control rate was 65.2% (95% CI: 54.3-75.0%). There
was no patient whose best overall response was rated as
complete response. The duration of stable disease was
5.4 months (95% CI: 4.1-6.2 months). The median TTF was
4.1 months (95% CI: 2.8-4.8 months), whereas the median
PFS was 5.4 months (95% CI: 4.1-6.2 months) (Figure 1A).
The median OS was 14.5 months (95% CI: 11.8-
17.0 months) (Figure 1B). No difference was noted in effi-
cacy between different groups of UGT1A1 polymorphisms.
The response rate, PFS, and OS in patients previously
treated with a regimen with bevacizumab were 7.2% (95%Table 3 Analysis of efficacy (N = 89)
Endpoint 95% CI
Response rate 10.1% 4.7-18.3%
Disease control rate 65.2% 54.3-75.0%
TTF 4.1 months 2.8-4.8 months
PFS 5.4 months 4.1-6.2 months
OS 14.5 months 11.8-17.0 monthsCI: 2.4-16.1%), 4.5 months (95% CI: 3.0-5.6 months), and
12.3 months (95% CI: 8.9-14.9 months), respectively, and
those in patients previously treated with a regimen with-
out bevacizumab were 20.0% (95% CI: 5.7-43.7%, p =
0.1102), 8.8 months (95% CI: 6.0-13.2 months, HR 2.100,
p = 0.0062) and 25.9 months (95% CI: 17.7-NA months,
HR 3.650, p < 0.0001) (Figure 2). Additional multivariate
analysis including sex, age, ECOG PS, primary tumor site,
and pre-treatment with bevacizumab as covariates re-
sulted in HR for OS of 3.773 (p < 0.001) and for PFS of
2.237 (p = 0.008).
The outcome was compared between patients who dis-
continued the first-line oxaliplatin-based treatment due to
progression of the primary disease and those who discon-
tinued it due to adverse events: the response rate, PFS,
and OS were 8.7% (95% CI: 2.4-20.8%), 3.8 months (95%
CI: 2.5-4.7 months) and 12.4 months (95% CI: 8.9-
15.1 months), respectively, in the former, while they were
11.6% (95% CI: 3.9-25.1%), 6.6 months (95% CI: 5.6-
9.4 months) and 17.0 months (95% CI: 12.7-23.3 months),
respectively, in the latter.Toxicity
Table 4 lists the adverse events observed in this study.
There was 1 patient (1.1%) of treatment-related death
and 1 patient (1.1%) of early death; that is, within 30 days
from the last dose. Granulocyte colony-stimulating fac-
tor was used in 24 (25.8%) patients.
The major grade 3 or higher adverse events observed
in the wild-type group were neutropenia in 33 patients
(62.3%), leucopenia in 11 patients (20.8%), diarrhea in 5
patients (9.4%), anorexia in 4 patients (7.5%), and fatigue
in 4 patients (7.5%), while the major grade 3 or higher
adverse events in the heterozygous group were neutro-
penia in 23 patients (57.5%, p = 0.6421), leucopenia in 11
patients (27.5%, p = 0.4486), diarrhea in 4 patients
(10.0%, p = 0.3014), anorexia in 2 patients (5.0%, p =
0.6964), and fatigue in 1 patient (2.5%, p = 0.3865). No
statistically significant difference was observed in any of
Figure 1 Kaplan-Meier curves for the study end points. (A) Progression-free survival (PFS), (B) Overall survival (OS).
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the heterozygous group.
Post chemotherapy
Table 5 shows the post chemotherapy after completion of
this study. Of the 24 patients (25.8%) who discontinued
the study treatment due to adverse events, 10 patients
(10.8%) did not meet the criteria for administration for
15 days or longer after the second cycle, and 5 of them
(5.4%) continued FOLFIRI plus bevacizumab or FOLFIRI
after recovering from the adverse events. There were 16
patients (18.0%) who received oxaliplatin-based regimen
after the study was completed, including 8 patients (9.0%)
who were refractory to and 8 patients (9.0%) who were in-
tolerable to oxaliplatin-based regimen.
Discussion
The BEVACOLOR study on the efficacy and safety of
standard chemotherapies such as second-line FOLFIRI orFOLFOX combined with bevacizumab for advanced or re-
current colorectal cancer, and the AVASIRI study on the
efficacy and safety of FOLFIRI plus bevacizumab with an
initial irinotecan dose of 150 mg/m2 have been reported
[17,18]. In this study, we demonstrated the efficacy and
safety of FOLFIRI plus bevacizumab regimen with an ini-
tial irinotecan dose of 180 mg/m2 in patients with ad-
vanced or recurrent colorectal cancer who discontinued
first-line oxaliplatin-based regimen and who were of the
wild-type or heterozygous group for UGT1A1 polymor-
phisms. The response rate, median PFS, and median OS
in this study were 10.1%, 5.4 months, and 14.5 months, re-
spectively. In the recently reported ML18147 study, the re-
sponse rate, median PFS, and median OS of the group
receiving second-line FOLFIRI plus bevacizumab were 5%,
5.7 months, and 11.2 months, respectively, and our results
compared favorably with those results [11].
When the patients received the first-line treatment,
bevacizumab was not yet approved in Japan. For this
Figure 2 Kaplan-Meier curves according to first-line treatment (oxaliplatin-based regimen) with/without bevacizumab. (A) Progresion-free
survival (PFS), (B) Overall survival (OS).
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treatment did not use bevacizumab during the first-line
treatment. We therefore conducted exploratory analyses
to investigate the efficacy of the first-line treatment
with/without bevacizumab, and there were statistically
significant differences in the median PFS and OS be-
tween the patients who received first-line bevacizumab
and those who did not (PFS; p = 0.0062, OS; p < 0.001).
There was no substantial difference in the patient char-
acteristics and contents of post chemotherapy between
the two groups. These results support the results re-
ported by Giantonio et al. in that second-line chemo-
therapy with bevacizumab is highly effective in patients
who do not receive first-line chemotherapy with bevaci-
zumab [16]. However, since the study population in-
cluded only 20 patients who were not treated withbevacizumab as a first-line, further studies are required
to confirm the effective use of bevacizumab. In addition,
KRAS mutation status on the efficacy was not collected
in this study, although frequently reported in the world
these days [19-21]. It is because KRAS assay was not yet
approved in Japan (approved in April, 2010) when our
study was started in May 2009, so that patients enrolled
in this study did not necessarily examine KRAS
mutation.
The incidence of adverse events and the median RDIs
indicated that the study treatment was tolerated. No
new issue of concern was found when compared with
previously reported studies [16-18]. In this study, 4 pa-
tients (4.5%) had the doses of both irinotecan and 5-FU
reduced simultaneously due to diarrhea. In other pa-
tients, the agents were safely administered by reducing
Table 4 Incidence of adverse events (N = 93)
Adverse event ≥Grade 1 ≥Grade 3
N % N %
Neutropenia 89 95.7 56 60.2
Leukopenia 89 95.7 22 23.7
Thrombocytopenia 12 12.9 0 0
Anemia 44 47.3 7 7.5
AST 27 29.0 0 0
ALT 32 34.4 1 1.1
Anorexia 60 64.5 6 6.5
Diarrhea 59 63.4 9 9.7
Nausea 61 65.6 0 0
Stomatitis 62 66.7 3 3.2
Vomiting 36 38.7 0 0
Fatigue 66 71.0 5 5.4
Cholinergic syndrome 18 19.4 0 0
Febrile neutropenia 1 1.1 1 1.1
Sepsis 2 2.2 2 2.2
Interstitial pneumonia 1 1.1 0 0
Hypertension 10 10.8 1 1.1
Bleeding 7 7.5 0 0
Pulmonary artery thrombosis 1 1.1 1 1.1
Pulmonary embolism 1 1.1 0 0
Embolism venous 1 1.1 1 1.1
Gastrointestinal perforation 2 2.2 2 2.2
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of the patients in this study had irinotecan or 5-FU dose
reduced due to grade 3 or higher diarrhea and grade 3
or higher neutropenia occurring simultaneously or due to
severe fatigue. These results further confirmed that FOL-
FIRI plus bevacizumab with an initial irinotecan dose
of 180 mg/m2 was a controllable regimen for Japanese
patients.
In this study, 10.8% of the treated patients did not re-
cover from adverse events within 15 days and thus
discontinued the study treatment. However, half of
them (5.4%) were able to continue on FOLFIRI plusTable 5 Post chemotherapy treatment (N = 89) Table
legend text
Post chemotherapy N %
Irinotecan-based regimen 54 60.7
Oxaliplatin-based regimen 16 18.0
Chemotherapy with bevacizumab 37 41.6
Chemotherapy with cetuximab 32 36.0
Chemotherapy with panitumumab 21 23.6bevacizumab or FOLFIRI as post chemotherapy after re-
covering from the adverse events. In addition, 18.0% of
the treated patients received post chemotherapy with
oxaliplatin after completing the study, of which 9.0%
were those who were refractory to oxaliplatin-based
regimen and the remaining 9.0% were those who were
intolerable to the regimen. The median survival time
among these patients (28.9 months) was longer than the
patients who did not receive post chemotherapy with
oxaliplatin (12.6 months). Thus, it seems meaningful to
consider reintroduction of oxaliplatin in patients who
discontinued oxaliplatin-based regimen as a first-line
treatment due to severe peripheral neuropathy, provided
that it has improved. These results suggest that, even
during third-line or later chemotherapy, administration
of irinotecan or oxaliplatin, the key drugs for colorectal
cancer chemotherapy, would contribute to prolonged
survival. More than one clinical trial has been conducted
on the reintroduction of oxaliplatin, which reported fa-
vorable results [22,23].
This study also included an exploratory assessment of
the efficacy and safety of each polymorphism in patients
of the wild-type or heterozygous group for UGT1A1*28
and *6 polymorphisms. As a result, no significant differ-
ence in efficacy and safety was suggested between these
two groups. We consider it necessary in future to deter-
mine appropriate doses irinotecan and evaluate the effi-
cacy and safety in Japanese patients of the homozygous
group for UGT1A1*28 and *6 polymorphisms.
Conclusions
FOLFIRI plus bevacizumab regimen with an initial irino-
tecan dose of 180 mg/m2 exhibited an adequate antitu-
mor effect and was confirmed to be manageable and
tolerable in Japanese patients with advanced or recurrent
colorectal cancer who had discontinued oxaliplatin-
based regimen.
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